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AngiogenesisAngiogenesis is a fundamental step in several important physiological events and pathological conditions
including embryonic development, wound repair, tumor growth and metastasis. PRKX was identiﬁed as a
novel type-I cAMP-dependent protein kinase gene expressed in multiple developing tissues. PRKX has also
been shown to be phylogenetically and functionally distinct from PKA. This study presents the ﬁrst evidence
that PRKX stimulates endothelial cell proliferation, migration, and vascular-like structure formation, which
are the three essential processes for angiogenesis. In contrast, classic PKA demonstrated an inhibitory effect
on endothelia vascular-like structure formation. Our ﬁndings suggest that PRKX is an important protein
kinase engaged in the regulation of angiogenesis and could play critical roles in various physiological and
pathological conditions involving angiogenesis. PRKX binds to Pin-1, Magi-1 and Bag-3, which regulate cell
proliferation, apoptosis, differentiation and tumorigenesis. The interaction of PRKX with Pin-1, Magi-1 and
Bag-3 could contribute to the stimulating role of PRKX in angiogenesis.mistry, NY State Institute for
rest Hill Road, Staten Island,
li@omr.state.ny.us (X. Li).
lsevier Inc.© 2011 Published by Elsevier Inc.Introduction
Angiogenesis, the formation of new blood vessels from pre-
existing vessels, is a fundamental step in several physiological events
including embryonic development, the female reproductive cycle,
placentation, and wound repair. It also plays an important role in
pathological conditions, such as tumor growth and metastasis,
rheumatoid arthritis, and diabetic retinopathy. In addition, the
elevation of angiogenesis is an important homeostatic process
contributing to the ischemic tissues of myocardial infarction and
stroke (Folkman and Shing, 1992; Hanahan and Folkman, 1996).
Angiogenesis is a complex process which includes the stimulation of
endothelial growth, degradation of extracellular matrix proteins,
migration of endothelial cells, and morphological differentiation of
endothelial cells to form tubes (Folkman and Shing, 1992; Hanahan
and Folkman, 1996). This process is controlled by pro-angiogenic
substances that are classiﬁed into two groups. One group consists of
direct inducers such as the vascular endothelial growth factor (VEGF)
and the basic ﬁbroblast growth factor which can promote theangiogenic process via activation of angiogenic signal pathways. The
other group is indirect inducers including TNF-α, transforming
growth factor-β, and interleukin-1β that act on endothelial cells to
induce the production of direct angiogenic factors from accessory cells
such as immune cells and tumor cells (Bussolino et al., 1997).
The human protein kinase X gene (PRKX) was identiﬁed as a serine/
threonine cAMP-dependent protein kinase gene on the X chromosome
at Xp22.3 and is highly expressed in a wide range of developing tissues
including kidney, lung, brain, heart, liver, muscle and pancreas (Klink et
al., 1995; Li et al., 2002; Li et al., 2005a, b; Schiebel et al., 1997;
Zimmermann et al., 1999). Phylogenetical analysis showed that PRKX is
a member of an ancient family of cAMP-dependent serine/threonine
kinases distinct fromthe classical PKA, PKB_Akt, PKC, SGK, andPKGgene
families. The catalytic domain of PRKX shares greater amino acid
homology with the Dictyostelium discoideum and Drosophila kinase
genes KAPC-DICDI andDC2 thanwithmammalian PKA genes (Anjard et
al., 1993; Kalderon and Rubin, 1988; Mann et al., 1992; Melendez et al.,
1995), it is plausible that PRKX and KAPC-DICDI might share unique
functions not conserved in PKA genes. PRKX has been suggested to
play important roles inmyeloidmaturation, neuronal differentiation,
renal epithelia migration and ureteric bud branching morphogenesis
(Blaschke et al., 2000; Li et al., 2009; Li et al., 2005a, b; Semizarov et
al., 1998). Previous studies have also demonstrated functional
differences between PRKX and PKA (Li et al., 2002; Zimmermann et
al., 1999). Zimmermann et al. (1999) showed that PRKX is a novel,
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cAMP concentrations than the holoenzyme of PKA. We also found
that PRKX activates renal epithelial cell migration and morphogen-
esis, which is a role not shared with PKA. Although PRKX is found to
be expressed in a wide range of developing tissues including heart
and aorta (Li et al., 2005a, b), no study has been conducted to
investigate its role in blood vessel development.
Our initial studies showed that PRKX is abundantly expressed in
the Mouse Aorta Endothelial cells (MAEs) as well as in the Human
Umbilical Vein Endothelial Cells (HUVECs). We thus hypothesized
that PRKX may play important roles in blood vessel formation and
angiogenesis. To test the hypothesis, we investigated the effects of
PRKX on endothelial cell migration, substrate adhesion and prolifer-
ation, which are essential processes involved in angiogenesis. In
addition, we also determined the role of PRKX in blood vessel
formation using HUVECs as an experimental model. Here we report
that PRKX expression stimulates HUVEC migration and proliferation
without affecting the cell adhesion. Over 60% knock-down of PRKX in
HUVECs and MAEs results in a signiﬁcant decrease in the migration,
adhesion and proliferation of both HUVECs and MAEs. In addition, we
show that PRKX expression stimulates HUVECs vascular-like structure
formation while PRKX knock-down results in a signiﬁcant reduction
and disruption in the vascular-like structure development. Further-
more, we demonstrate that PKA has a distinct effect from PRKX in this
regard. In contrast to the stimulatory effect of PRKX, PKA results in an
inhibitory effect on HUVEC vascular-like structure formation in
Matrigel.
Materials and methods
Construction of PRKX expression lentiviral vectors
The generation of the recombinant peGFP/PRKX, pFLAG/PRKX, and
the kinase dead pFLAG/PRKX/K78R fusion protein constructs has been
described previously (Li et al., 2002). The kinase dead GFP fusion
protein encoding construct peGFP/PRKX/K78R was derived by point
mutagenesis of peGFP/PRKX. The constitutively active PRKX kinase
construct peGFP/PRKX.ca was engineered by point mutagenesis (His
93 changed to Gln, and Trp 202 changed to Arg) as described for PKA
kinase (Orellana et al., 1993). PRKX viral-expressing constructs were
generated using the VVC self-inactivating lentiviral vector. The VVC
lentivector was derived from the substitution of the U3 region of the
5′LTR of the pHR/CMV vector (Gusella et al., 2002) with the human
early cytomegalovirus promoter. PRKX transgenes were expressed by
cloning into the polylinker downstream of an internal constitutively
active CMV promoter. The functionalities and titers of the PRKX viral
constructs were tested on cultured HeLa-Tat cells. Infectious viral
supernatants with a titer of N1×107 transducing units (TU)/ml were
produced by transient transfection of 293T cells using Lipofectamine
2000 (Invitrogen, San Diego, CA) with 8 μg of VVC-peGFP/PRKX,
VVC-pFLAG/PRKX/K78R, or VVC-peGFP/PRKX.ca co-transfected with
5.0 μg of the pCMVΔR8.2 plasmid producing the viral proteins, and
2.5 μg of the pMD.G plasmid expressing the pseudotyping VSV
glycoprotein (VSVG) (Naldini et al., 1996). After 24 h, the medium
was replaced with complete medium supplemented with 4 mM
sodium butyrate, and supernatants were collected 48 h later. The titer
(TU/ml) was determined 48 h after infection of 3×104 HeLa-Tat cells/
well in 24-well plates by scoring the number of eGFP expressing cells
using ultraviolet microscopy.
Dissection and isolation of mice aorta endothelia (MAE)
4-weekoldmicewere sacriﬁcedwithNembutal. Aortaswere removed
and placed in DMEM containing penicillin/streptomycin/fungizone. After
removal of all the connective tissue and adventitia under a dissecting
microscope in the tissue culture hood, the vessels were cut longitudinallyand the endothelium very gently scraped off using the ﬂat edge of
curved forceps or a cotton swab. After a media rinse, the strips were
cut into 3–5 mm pieces before the digestion in 5 ml DMEM+
penicillin/streptomycin/fungizone and collagenase type II (175 U/ml).
After centrifugation at 500 rpm for 1 min, pieces were resuspended
in 5 ml DMEM+penicillin/streptomycin/fungizone with collage-
nase type II (175 U/ml) and Elastase type III (0.25 mg/ml). When
the pieces were completely dissolved, digestion was stopped by
dilution with an equal volume of DMEM containing penicillin/
streptomycin/fungizone and 20% FBS. After centrifugation at
1000 rpm for 5 min the supernatant was removed completely and
cells suspended in DMEM containing penicillin/streptomycin/
fungizone and 20% FBS. Cells were then maintained by feeding
with fresh DMEM containing penicillin/streptomycin/fungizone and
20% FBS every other day.
Cell culture and viral transduction studies
Human umbilical vein endothelial cells (HUVECs) were purchased
from LONZA, USA and used between passages 3–6. The cells were
grown in M199 medium supplemented with 20% fetal bovine serum
(FBS), 100 units/ml penicillin, 100 μg/ml streptomycin, 3 ng/ml
β-FGF, and 5 units/ml heparin at 37 °C under 5% CO2/95% air. HUVECs
were transduced with constitutively active VVC-peGFP/PRKXca, or
kinase-dead VVC-peGFP/PRKX.d, or VVC-peGFP viral vector alone
containing 1×107 infectious units of virus (IFU). The medium was
replaced with fresh medium 12 h after infection.
PRKX gene silencing with lentiviral shRNA
Both human and mouse PRKX lentiviral shRNA, as well as control
shRNA lentiviral particleswere purchased fromSanta CruzBiotechnology.
HUVECs and mouse endothelial cells were transduced with PRKX
shRNA viral stock containing 1×106 infectious units of virus (IFU)
and control shRNA viral stock, respectively, according to the
manufacturer's instructions. The medium was replaced with fresh
medium 12 h after infection and gene-silencing effects were
analyzed after 48 h by quantitative real-time (RT)-PCR and Western
immunoblot.
Quantitative real-time polymerase chain reaction (qRT-PCR)
Total RNA was isolated from cells using ISOGEN-LS (Nippon Gen
Co). cDNAwas prepared from total RNA using a cDNA Synthesis Kit for
RT-PCR (Roche Diagnostics). The designed primers (GGACTTT-
GGGTTCGCCAAGA, TTCCGTGGCCCTTGCTCT) for PRKX were made in
the Sequence Service Center at Mount Sinai School of Medicine and
then veriﬁed in our laboratory. For ampliﬁcation, initial denaturation
at 95 °C for 10 minwas followed by 15 s at 95 °C, 15 s at 62 °C and 10 s
at 72 °C for 40 cycles. The expected size of PCR products was
conﬁrmed by agarose gel electrophoresis.
Western immunoblot analysis
Cell extracts were prepared in lysis buffer, pH7 containing 1%
Triton X-100, 0.5% NP-40, 150 mM NaCl, 0.05 M Tris, pH 8.0, 1 mM
EDTA, 1 mM PMSF, 10 mg/ml leupeptin, 10 mg/ml pepstatin, 1 mg/ml
aprotinin, and chymostatin 100 mg/ml for 30 min at 4 °C, clariﬁed at
15,000×g for 15 min. The soluble proteins in the supernatant were
mixed with sample buffer containing 120 mg/ml Tris base, 10% SDS,
10% glycerol, 5% beta-mercaptoethanol and 0.02 mg/ml bromophenol
blue and then heated at 100 °C for 3 min. Proteins were separated by
10% SDS-PAGE gradient polyacrylamide gels and electrophoretically
transferred to nitrocellulose membranes (Schleicher & Schuell) for
0.5 h at 150 mA in Tris–glycine–methanol. After blocking in 5% normal
dried milk for 1 h, membranes were probed with the previously
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RB1029 antibody, Abgent, San Diego) for 2 h at room temperature,
then incubated with horseradish peroxidase-coupled secondary
antibody (Sigma) for 1 h, washed extensively and visualized by
enhanced chemiluminescence (ECL, Amersham) and exposure to
Hyperﬁlm.
Immuno-histochemistry and immuno-ﬂuorescence staining
Cells cultured on slides were ﬁxed with 2% paraformaldehyde and
permeabilized with 0.1% Triton X-100 followed by incubation in 0.3%
H2O2 in methanol to block endogenous peroxidase activity. Cells were
then incubated with 10% normal goat or rabbit serum in PBS, prior to
45 min incubation in primary antibody diluted 2% BSA/PBS. After 3
washes of 5 min each in PBS-Tween 20 (0.02%), cells were incubated
for 45 min each with biotinylated goat anti-rabbit IgG and avidin–
biotin peroxidase (Vectastain Elite, Vector Laboratories). After 2
washes in Tris-buffered saline (TBS), color development was carried
out for 15 min using amino-ethylcarbazole as substrate. Cells were
viewed under a Nikon FXA-Microphot microscope equipped with
Nomarski optics. For ﬂuorescence staining, the secondary antibodies,
donkey anti-mouse–Alexa 488 or donkey anti-rabbit–Alexa 568
(Molecular Probes), were used in 1:250 dilution, and incubation
was carried out for 2 h at 37 °C. After 3 washes in PBS, immuno-
ﬂuorescence analysis was carried out using a multi-photon laser
scanning microscope with inverted conﬁguration using immersion
lenses (BioRad Radiance 2000, MSSM core facilities).
Modiﬁed Boyden chamber migration assay
Cells from different experimental groups were washed with
serum-free medium and then labeled with the ﬂuorescence probe
calcein AM (Molecular Probes, Eugene, OR). 2000 cells from each
groupwere then suspended in 0.3 ml of DMEMplus 1% FBS and plated
onto transwells with 8 μm pores (Fluoroblock system, Falcon). The
lower well contained 0.8 ml of DMEM plus 1% FBS. After 4 h, the
transwells were transferred to new wells that contained 10% FBS to
establish a serum gradient. The number of labeled cells that migrated
through the pore to the lower chamber was measured by the
appearance of ﬂuorescence at 4 h, 8 h, 18 h and 24 h using an HTS
7000 microﬂuorimeter (Perkin Elmer Cetus, Wellesley, MA).
Cell-matrix adhesion assay
Cells from different experimental groups were washed twice with
serum free medium. 5000 cells were plated per well on 96-well tissue
culture plates precoated with ﬁbronectin (20 μg/ml). After 6 h of
attachment in serum-free tissue culture media, all unattached cells
were washed off by gentle aspiration and a wash in PBS. Adherent cell
numbers were determined by the colorimetric aqueous MTS assay
(Cell Titer 96TM Aq, Promega) and automated reading on a plate
reader (Biorad) and levels calculated versus standard curves.
Cell proliferation assay
Cells from different experimental groups were washed twice with
serum free medium. 5000 cells were plated per well in 96-well tissue
culture plates. After 72 h incubation at 37 °C, cell proliferation was
determined by the colorimetric aqueous MTS assay (Cell Titer 96TM
Aq., Promega).
The Matrigel tube formation assay
The formation of vascular-like structures by HUVECs on growth
factor reducedMatrigel was performed to determine the effect of PRKX on
angiogenesis. Twenty four-well culture plates were coated with
Matrigel according to the manufacturer's instructions. HUVECs of
different groups were incubated in M199 containing 1% FBS for 6 h
and plated onto a layer of Matrigel at a density of 2000 cells/well.
Matrigel cultures were incubated at 37 °C for 20 h to 26 h. Tube
formation was observed using an inverted phase contrast microscope
and images were captured with a video graphic system. The degree of
vascular-like structure formation was quantiﬁed by measuring the
length of the structures in 5 randomly chosen low-power ﬁelds
(×100) from each well using Image J (National Institute of Health).
Results
PRKX expression in HUVECs and MAEs
To investigate the role of PRKX in angiogenesis, we ﬁrst carried out
immunohistochemistry and immunoﬂuorescence studies to deter-
mine whether PRKX is expressed in HUVECs and MAEs. HUVECs were
purchased from LONZA (USA) andMAEswere isolated from the aortas
of 4 week old mice. The isolated MAEs were distinguished by
vitronectin (VN) as shown in Fig. 1 (left panel), since previous studies
have demonstrated that vitronectin, the major ligand for αvβ3, was
associated with the basal surface of endothelial cells in the embryo
stage (Drake et al., 1995). Our results demonstrated that PRKX is
abundantly expressed in the cytoplasm and nuclei of HUVECs (Fig. 1,
right panel) and MAEs (Fig. 1, middle panel).
PRKX expression stimulates endothelial cell migration
In this study, we constructed lentiviral PRKX expression vectors
including: a constitutively active viral vector (VVC-peGFP/PRKX.ca);
and a kinase-dead viral vector (VVC-peGFP/PRKX.d) (Materials and
methods). After conﬁrming the expression of VVC-peGFP/PRKX.ca in
HUVECs (Fig. 2a), a modiﬁed Boyden chamber (Fluroblock) migration
assay was carried out to determine the effect of PRKX on HUVEC cell
migration. A signiﬁcant increase in cell migration was measured in
HUVECs that over-expressed active PRKX after transduction with
constitutively active VVC-peGFP/PRKX.ca. By contrast, no signiﬁcant
increase in migration was seen in untransduced cells; in cells
transduced with empty vector alone (VVC-peGFP); or in cells
transduced with inactive VVC-peGFP/PRKX.d (Fig. 2b).
To further conﬁrm the stimulatory effect of PRKX on endothelial
cell migration, we knocked down PRKX in both HUVECs and MAEs
utilizing a lentiviral shRNA approach. We observed cell cultures
treated with PRKX lentiviral shRNA (experimental group) and the
controls treated with shRNA lentiviral vector alone under the
microscope. There was no obvious difference found in cell appearance
between the two groups. The cells in both groups look healthy, and
there are few dead cells observed. Our results showed that HUVECs
with over 65% knock-down of PRKX (determined byWestern blot and
qRT-PCR, Figs. 3a, b and c) were signiﬁcantly less migratory than
controls (Fig. 3d). In addition, we were able to show that MAEs
demonstrated a signiﬁcant decrease in migration after N60% knock-
down of PRKX (Figs. 3e, f, g and h). Collectively, these results strongly
suggest that PRKX plays a crucial role in mouse and human
endothelial cell migration.
PRKX expression is important in maintaining the adhesion property of
endothelia
Next, we examined the effects of PRKX on endothelial cell adhesion
to extracellular matrix (ECM). No signiﬁcant difference in HUVEC cell
adhesion to ICAM-1(Inter-Cellular Adhesion Molecule 1) was seen
before or after transduction with the empty lentivector (VVC-peGFP);
constitutively active VVC-peGFP/PRKX.ca (overexpression of active
Fig. 1. PRKX expression in HUVECs and MAEs. Immunocytochemistry of PRKX endogenous expression in the cytoplasm and nuclei of MAEs (middle panel, scale bar, 25 μm) and
HUVECs (right panel, scale bar, 25 μm). Left panel shows the MAEs distinguished by vitronectin (VN, scale bar, 2 μm) using immunoﬂuorescence.
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and 67% knock-down of PRKX by lentiviral-mediated shRNA in
HUVECs and MAEs respectively (Figs. 4b, c, d and e), both HUVECs
and MAEs showed a signiﬁcant decrease in ECM-adhesion compared
to controls (Figs. 4f and g). These results suggest that the physiological
level of PRKX may be important in maintaining the normal levels of
ECM-adhesion in human and mouse endothelial cells.
PRKX expression stimulates endothelial cell proliferation
Proliferation is another important component of angiogenesis.
Thus, the effects of PRKX on endothelial cell proliferation were also
examined. Our results demonstrated that HUVECs, overexpressing
active PRKX after transduction with VVC-peGFP/PRKX.ca, showed
signiﬁcantly increased levels of cell proliferation measured at a 72-
hour time-point. By contrast, no signiﬁcant increases in proliferation
were detected in the three control groups (untransduced HUVECs,
HUVECs transduced with empty vector VVC-peGFP alone, or trans-
duced with VVC-peGFP/PRKX.d) (Fig. 5a). To further determine the
physiological role of PRKX on endothelial cell proliferation, PRKX was
knocked down in both HUVECs and MAEs using the shRNA approach
followed by examination of the cell proliferation at a 72-hour time-
point. Our results showed that 66% and 69% knock-down of PRKX in
HUVECs and MAEs respectively (Figs. 5b, c, d and e) resulted in
signiﬁcant decreases in proliferation of both cell lines, as compared
with controls (Figs. 5f and g). These results suggest that PRKX also
plays an important role in endothelial cell proliferation.
PRKX expression promotes the formation of vascular-like structures
To further investigate the role of PRKX in angiogenesis, we
conducted Matrigel Tube Formation assays on HUVECs to monitor1
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Matrigel (Figs. 7a, b and c).
Discussion
To our knowledge, this study presents the ﬁrst evidence that PRKX
plays a stimulating role in angiogenesis. We showed that PRKX iscritically involved in the regulation of all the three essential processes
for angiogenesis including proliferation, migration, and vascular-like
structure formation of endothelial cells. Importantly, this study also
demonstrated that PRKX and PKA play different roles in angiogenesis
although their catalytic activities are both regulated by cAMP. In
contrast to the stimulatory role of PRKX in angiogenesis, PKAwas shown
to inhibit HUVECs' vascular-like structure formation in Matrigel.
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molecules, such as prostaglandin E2 (PGE2) (Namkoong et al., 2005),
thyrotropin (Hoffmann et al., 2004), parathyroid hormone-related
peptide (Akino et al., 2000), and norepinephrine (Fredriksson et al.,
2000), have been shown to promote the angiogenic process via
the activation of cAMP-dependent protein kinases. Most recently,
Namkoong et al. (2009) demonstrated that forskolin drastically
increased endothelial cell proliferation, migration, and tube formationin vitro as well as neovascularization in vivo. They suggested that
forskolin increases angiogenesis through the coordinated cross-talk of
VEGF expression and PI3K/Akt/eNOS signaling. Forskolin is a diterpene
extracted from plants and exerts its biological action by binding to
speciﬁc cellular receptors known as adenylyl cyclase isoforms, such as
AC1 to AC8. The enzymes responsible for the synthesis of cAMP from
ATP results in the increase of cellular cAMP, which is related to the
phosphorylation and activation of multiple selective cellular
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Fig. 5. Effects of PRKX in endothelial cell proliferation. a: Proliferation assay in HUVECs without untransduced or transduced with three types of viral constructs. Cell proliferationwas
determined after 72 h. Values are mean±SE from two independent experiments in triplicates. **pb0.01. b and c: PRKX knock-down in HUVECs assessed by Western blot, n=6,
**pb0.01. d and e: PRKX knock-down in MAEs assessed by Western blot, n=6, **pb0.01. f: Proliferation assay in HUVECs after PRKX knock-down. Values are mean±SE from two
independent experiments in triplicates. **pb0.01. g: Proliferation assay in MAEs after PRKX knock-down. Values are mean±SE from two independent experiments in triplicates.
**pb0.01.
481X. Li et al. / Developmental Biology 356 (2011) 475–485substrates including cAMP-dependent protein kinases (Cullere et al.,
2005; D'Angelo et al., 1997; Defer et al., 2000).
The identiﬁcation of human PRKX challenges the previous concept,
in which the biological functionsmediated by cAMP-dependent protein
kinases have been regarded as the functions of PKA. PRKX is not a PKA,
but is a cAMP-dependent protein kinase. PRKX holoenzyme is localized
in the cytoplasm. Activation by cAMP, the catalytic subunit of PRKX is
then disassociated from the regulatory subunit and translocated into
thenucleus,where it exerts biological function. PRKXhas been shown tobe activated at lower cAMP concentrations than the PKA and is
functionally distinct from PKA (Li et al., 2002; Zimmermann et al.,
1999). These ﬁndings suggest that some of the cAMP-mediated
functions may be undertaken by PRKX, rather than by PKA. This may
also explain the complexity of cAMP-mediated biological functions.
Previous studies showed that overexpression of the PKA catalytic
subunit induces apoptosis in proliferating endothelial cells and inhibits
angiogenesis (Kim et al., 2002). In this study, we demonstrated that
overexpression of PKA catalytic subunit suppressed the HUVECs tube
482 X. Li et al. / Developmental Biology 356 (2011) 475–485formation in Matrigel, which supports the inhibitory role of PKA in
angiogenesis. However, previous studies have also shown that
adenylate cyclase/protein kinase A signaling pathway enhances
angiogenesis through induction of vascular endothelial growth factor
(VEGF). In this regard, Amano et al. (2001) demonstrated that
application of 8-bromo-cAMP or forskolin facilitated angiogenesis and
VEGF induction was conﬁrmed after the application of 8-bromo-cAMP.a
c
b
Fig. 6. Effect of PRKX on the formation of capillary-like structures in HUVECs. a and c: Ma
constructs (a: low magniﬁcation, c: higher magniﬁcation). b: The tube length of the capilla
independent experiments in triplicates **pb0.01. d and e: PRKX knock-down in HUVECs as
knock-down (low and high magniﬁcation). g: The tube length of the capillary-like struc
experiments in 4 replicates. **pb0.01.We reckon that the angiogenic effects of 8-bromo-cAMP and forskolin,
as well as other inducers including PGE2, thyrotropin, parathyroid
hormone-related peptide and norepinephrine, may involve the activa-
tion of PRKX, other than PKA. Since PRKX and PKA are activated at
different cAMP concentrations (Zimmermann et al., 1999), it could help
to explain why cAMP could mediate both stimulatory and inhibitory
effects on angiogenesis.0
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Fig. 6 (continued)
483X. Li et al. / Developmental Biology 356 (2011) 475–485Angiogenic inducers lead to an increase in endothelial cell
migration, proliferation, and tube-like structure formation by two
distinct action modes, which are direct activation of the angiogenic
signal pathway and indirect production of angiogenic factors. The
well-known angiogenic molecule VEGF is produced in a transcrip-
tional manner by stabilization of the O2-sensitive transcription factor
HIF-1α and phosphorylation of CREB (Forsythe et al., 1996; Wu et al.,
2007). Studies have demonstrated a link between cAMP-dependent
kinases and up-regulation of VEGF expression (Namkoong et al.,
2009). In addition, several signaling pathways including PI3K/Akt and
MEK/ERK cascade have been shown to be involved in the regulation of
endothelial cell migration, proliferation and vascular-like structure
formation (Chai and Jones, 2004; Hood et al., 2003). Both PI3K/Akt and
MEK/ERK signaling can be modulated by cAMP-dependent kinases.
Therefore, it is of important signiﬁcance to investigate whether PRKX
exerts its stimulatory role in angiogenesis though the modulation of
VEGF and/or the signaling pathways of PI3K/Akt and MEK/ERK.In addition, PRKX amino-acid sequence identiﬁed two putative
proline-rich WW-domain binding sites phospho-SP/-TP and PPxY
(Komuro et al., 2003; Sudol et al., 2001; Sudol and Hunter, 1998).
Previously membrane-binding analyses showed strong binding of
PRKX to three proteins, Pin-1, Magi-1 and Bag-3, particularly through
the phospho-SP/-TP site in vitro (Li et al., 2009). PRKX has also been
shown to co-immunoprecipitated with Pin-1 (Li et al., 2009). Pin-1,
Bag-3 and Magi-1 have been implicated in a variety of cellular
processes, including proliferation, apoptosis, development, differen-
tiation and tumorigenesis (Lu, 2004; Lu et al., 2002; Wulf et al., 2004).
Furthermore, the phosphorylation of the Pin-1 WW domain on Ser16
has been proposed as a new mechanism critical for the regulation of
PIN-1 function (Lu et al., 2002). Cell-free in vitro studies have shown
that PRKX is capable of phosphorylating PIN-1, MAGI-1, and BAG-3 (Li
et al., 2009). Thus, it is also important to further investigate whether
the role of PRKX in angiogenesis involves the interaction with Pin-1,
Bag-3 and Magi-1.
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Fig. 7. Effect of PRKX on the formation of capillary-like structures in HUVECs. a and b: Matrigel assay of HUVECs transduced with PKAc (low and high magniﬁcation). c: The tube
length of the capillary-like structure of HUVECs was analyzed and the values are mean±SE from two independent experiments in triplicates. *pb0.05.
484 X. Li et al. / Developmental Biology 356 (2011) 475–485Taking together, our ﬁndings suggest that PRKX is an important
kinase engaged in the modulation of angiogenesis. Abnormal
regulation of PRKX could contribute to various pathological conditions
involving angiogenesis such as embryonic development defects,
tumor growth and metastasis, rheumatoid arthritis, diabetic retinop-
athy and interruption of wound repair. PRKX has not been well
studied in spite of its abundant expression in a wide range of
developing tissues including the kidney, brain, heart, lung, liver,
pancreas and blood vessels. PRKX shares great amino acid homology
with KAPC-DICDI shown to play an important role in the development
of Dictyostelium discoideum (Blaschke et al., 2000; Li et al., 2008; Li et
al., 2005a, b; Primpke et al., 2000; Semizarov et al., 1998), suggesting
that PRKXmight also play critical roles in the development of multiple
human tissues.
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